Tenecteplase Shift in Acute Ischemic Stroke Care

In Pakistan’s overcrowded emergency departments, every minute counts when a patient arrives with acute ischemic stroke. The shift toward single-bolus tenecteplase offers a practical way to deliver thrombolysis faster, reduce preparation steps, and potentially improve door-to-needle times without adding complexity for already stretched teams.

What Changed / Why It Matters

Alteplase has long been the standard intravenous thrombolytic, given as a bolus followed by a one-hour infusion. Tenecteplase, a genetically modified tissue plasminogen activator, is administered as a single weight-based intravenous bolus over seconds. This pharmacokinetic profile simplifies logistics: no infusion pump setup, fewer line complications, and easier transfer if the patient needs endovascular therapy.

Large randomized trials and meta-analyses have shown tenecteplase to be at least non-inferior to alteplase for functional outcomes in eligible patients treated within the approved time window, with comparable safety regarding symptomatic intracranial hemorrhage. Guidelines in several regions now endorse tenecteplase as a reasonable alternative, particularly where workflow efficiency matters. For busy public ERs in Pakistan, the single-bolus approach can cut treatment delays caused by pump availability, staffing shortages, or inter-hospital transfers. It also aligns well with drip-and-ship models common in our healthcare system. Careful patient selection—based on last-known-well time, NIHSS, imaging to exclude hemorrhage, and standard contraindications—remains essential. Dosing is typically 0.25 mg/kg (maximum 25 mg) for stroke, distinct from the cardiac dose.

Patient Takeaway

If you or a family member develops sudden face droop, arm weakness, or speech difficulty, call emergency services immediately and note the exact time symptoms started. Faster arrival increases the chance of receiving thrombolysis, whether alteplase or tenecteplase. Ask the treating team about the chosen agent and the rationale; both aim to dissolve the clot and restore blood flow. After treatment, close monitoring in a stroke-capable unit is required. Secondary prevention—blood-pressure control, antiplatelets or anticoagulation as indicated, statins, diabetes management, smoking cessation, and rehabilitation—determines long-term recovery.

ایک فوری فیصلہ زندگی بچا سکتا ہے؛ علامات ظاہر ہوتے ہی ہسپتال پہنچیں۔

Disclaimer: This post is for educational purposes only and does not constitute personalized medical advice or diagnosis. Stroke care decisions must be made by qualified clinicians using current imaging, labs, and individual patient factors. Always follow local protocols and regulatory approvals.

Book consultation: https://rx.drwasifmalik.com | WhatsApp +923000874232 Dr. Wasif Rizwan Malik | MBBS, FCPS (Neurosurgery) | PMDC 47983-P | Consultant Neurosurgeon, Faraz Hospital, Bahawalpur.

Educational only — not a substitute for clinical consultation. This daily brief is separate from the weekly Neuro Council deep-dive.

Book a consultation